Teclistamab Phase 3 Trial in Relapsed/Refractory Myeloma Reaches Primary…

A Phase 3 clinical trial (NCT05572515) evaluating teclistamab monotherapy for relapsed or refractory multiple myeloma reached its primary completion on 2025-10-13. This study, which enrolled 614 participants, compares teclistamab against standard treatment regimens.

Background

The purpose of this study is to compare the efficacy of teclistamab with pomalidomide, bortezomib, dexamethasone (PVd) or carfilzomib, dexamethasone (Kd) in Part 1 and to further characterize safety and efficacy of an alternative dosing for teclistamab in Part 2 in participants with relapsed or refractory multiple myeloma.

Trial design

The Phase 3 study, NCT05572515, is titled 'A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma.' It enrolled 614 participants with relapsed or refractory multiple myeloma. The trial design compares teclistamab monotherapy against established regimens: pomalidomide, bortezomib, and dexamethasone (PVd) or carfilzomib and dexamethasone (Kd).

What this means

The primary completion of this Phase 3 trial signifies a key milestone in the evaluation of teclistamab for relapsed or refractory multiple myeloma. This event indicates that the study has reached the point where data collection for its primary objectives is largely complete, moving closer to potential analysis and reporting of results. The comparison against current standard-of-care regimens like PVd and Kd is crucial for understanding teclistamab's potential role in this patient population.

Source

Information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The record for study NCT05572515, titled 'A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma,' was updated to reflect primary completion on 2025-10-13 on clinicaltrials.gov.